reports
- Dave Nicoski
- Ross LaDuke
NXPIN NXP SEMICONDUCTORS NV
RJF RAYMOND JAMES FINANCIAL INC.
PNC PNC FINANCIAL SERVICES GROUP INC.
Z ZILLOW GROUP INC. CLASS C
WU WESTERN UNION COMPANY
WAIR WESCO AIRCRAFT HOLDINGS INC
V VISA INC. CLASS A
UCTT ULTRA CLEAN HOLDINGS INC.
TTWO TAKE-TWO INTERACTIVE SOFTWARE INC.
TOL TOLL BROTHERS INC.
T AT&T INC.
SPKE SPARK ENERGY INC-CLASS A
SNR NEW SENIOR INVESTMENT GROUP INC
SFLY SHUTTERFLY INC.
SATS ECHOSTAR CORPORATION CLASS A
RGA REINSURANCE GROUP OF AMERICA INCORPORATED
PTLA PORTOLA PHARMACEUTICALS INC.
PIRS PIERIS PHARMACEUTICALS
PFG PRINCIPAL FINANCIAL GROUP INC.
NDAQ NASDAQ INC.
MAR MARRIOTT INTERNATIONAL INC. CLASS A
KBH KB HOME
IVZ INVESCO LTD.
HTH HILLTOP HOLDINGS INC.
HIBB HIBBETT SPORTS INC.
H HYATT HOTELS CORPORATION CLASS A
FBIZ FIRST BUSINESS FINANCIAL SERVICES
F FORD MOTOR COMPANY
EPZM EPIZYME INC.
ECPG ENCORE CAPITAL GROUP INC.
EBSB MERIDIAN BANCORP INC
DISH DISH NETWORK CORPORATION CLASS A
DEA EASTERLY GOVERNMENT PROPERTIES INC
CZR CAESARS ENTERTAINMENT CORPORATION
CMRX CHIMERIX INC
CLGX CORELOGIC INC.
CIR CIRCOR INTERNATIONAL INC.
CBOE CBOE GLOBAL MARKETS INC
CASH META FINANCIAL GROUP INC.
BEN FRANKLIN RESOURCES INC.
AN AUTONATION INC.
AMP AMERIPRISE FINANCIAL INC.
ALL ALLSTATE CORPORATION
AEIS ADVANCED ENERGY INDUSTRIES INC.
PRU PRUDENTIAL FINANCIAL INC.
WLH WILLIAM LYON HOMES CLASS A
MET METLIFE INC.
MHK MOHAWK INDUSTRIES INC.
MAS MASCO CORPORATION
ADTN ADTRAN INC.
ETH ETHAN ALLEN INTERIORS INC.
IBP INSTALLED BUILDING PRODUCTS INC.
ITI ITERIS
NAVI NAVIENT CORP
UEIC UNIVERSAL ELECTRONICS INC.
USAT USA TECHNOLOGIES
WSO WATSCO INC.
SITE SITEONE LANDSCAPE SUPPLY INC.
SPOK SPOK HOLDINGS
ARNC HOWMET AEROSPACE INC.
LCII LCI INDUSTRIES
ATNX ATHENEX
ZG ZILLOW GROUP INC. CLASS A
CBLK CARBON BLACK
WH WYNDHAM HOTELS & RESORTS INC.
Pieris Pharmaceuticals to Present at Investor Conferences in November
Pieris Pharmaceuticals to Present at Investor Conferences in November BOSTON, Nov. 08, 2018 (GLOBE NEWSWIRE) -- Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for cancer, respiratory and other diseases, announced today that members of the management team will present at the following investor conferences in November: Jefferies London Healthcare ConferenceThursday, November 15, 2018 at 9:20AM GMT at the Waldorf Hilton (Aldwych) Hotel in London. A webcast of the Com...
Pieris Pharmaceuticals Reports Third Quarter 2018 Financial Results an...
Pieris Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Corporate Update Company to Host an Investor Conference Call on Wednesday, November 7, 2018 at 8:00 AM EST BOSTON, Nov. 07, 2018 (GLOBE NEWSWIRE) -- Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory, cancer and other diseases, today reported financial results for the third quarter of 2018 ended September 30, 2018 and provided an update on the Company’s recent and future dev...
Pieris Pharmaceuticals to Host Third Quarter 2018 Investor Call and Co...
Pieris Pharmaceuticals to Host Third Quarter 2018 Investor Call and Corporate Update on November 7, 2018 BOSTON, Oct. 31, 2018 (GLOBE NEWSWIRE) -- Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for cancer, respiratory and other diseases, announced today that it will host a third quarter 2018 investor call on Wednesday, November 7, 2018 at 8:00 AM (EDT) to discuss financial results and provide a corporate update. To access the call, participants may dial 877-407-8920 (US & Canada) ...
Pieris Pharmaceuticals Appoints Matthew L. Sherman, M.D., to its Board...
Pieris Pharmaceuticals Appoints Matthew L. Sherman, M.D., to its Board of Directors BOSTON, Oct. 25, 2018 (GLOBE NEWSWIRE) -- Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for cancer, respiratory and other diseases, announced today that Matthew L. Sherman, M.D., has joined the Company’s Board of Directors. Dr. Sherman is a physician-scientist with clinical development expertise in oncology, hematology and pulmonary diseases across large pharma, biopharma and ventur...
Pieris Pharmaceuticals to Present Preclinical Data for 4-1BB/PD-L1 Bis...
Pieris Pharmaceuticals to Present Preclinical Data for 4-1BB/PD-L1 Bispecific PRS-344/ONC0055 at the Society for Immunotherapy of Cancer (SITC) Annual Meeting BOSTON, Oct. 02, 2018 (GLOBE NEWSWIRE) -- Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for cancer, respiratory and other diseases, announced today that preclinical data for PRS-344/ONC0055 will be presented at the Society for Immunotherapy of Cancer (SITC) Annual Meeting in Washington, D.C. PRS-344/ONC0055 is...
Pieris Pharmaceuticals to Present at Investor Conferences in October
Pieris Pharmaceuticals to Present at Investor Conferences in October BOSTON, Sept. 25, 2018 (GLOBE NEWSWIRE) -- Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for cancer, respiratory and other diseases, announced today that members of the management team will present at the following upcoming investor conferences in October: Cantor Fitzgerald Global Healthcare ConferenceTuesday, October 2, 2018 at 11:30AM EDT at the InterContinental New York Barclay Hotel in New Yor...
Pieris Pharmaceuticals to Present Preclinical Data for Inhaled IL-4Rα...
Pieris Pharmaceuticals to Present Preclinical Data for Inhaled IL-4Rα Antagonist AZD1402/PRS-060 at the ERS International Congress 2018 BOSTON, Sept. 14, 2018 (GLOBE NEWSWIRE) -- Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for cancer, respiratory and other diseases, announced today that preclinical data for AZD1402/PRS-060 will be presented at two poster sessions at the European Respiratory Society (ERS) International Congress 2018 in Paris, France. PRS-060, an in...
Pieris Pharmaceuticals Appoints Peter Kiener, D.Phil. to its Board of ...
Pieris Pharmaceuticals Appoints Peter Kiener, D.Phil. to its Board of Directors BOSTON, Sept. 10, 2018 (GLOBE NEWSWIRE) -- Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for cancer, respiratory and other diseases, announced today that Peter Kiener, D.Phil. has joined the Company’s Board of Directors. Dr. Kiener is an industry veteran with extensive experience across the entire value chain of biopharmaceutical research and development. Most recently, Dr. Kiener serve...
Pieris Pharmaceuticals Announces Dosing of First Patient in Phase I Co...
Pieris Pharmaceuticals Announces Dosing of First Patient in Phase I Combination Trial for PRS-343 Plus Anti-PD-L1 Immunotherapy BOSTON, Sept. 04, 2018 (GLOBE NEWSWIRE) -- Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for cancer, respiratory and other diseases, announced today that it has dosed the first patient in the Company’s Phase 1 combination clinical trial of PRS-343, its lead proprietary immuno-oncology drug candidate targeting HER2 and 4-1BB, plus atezolizumab (Tecentriq®)...
Pieris Pharmaceuticals to Present at the 20th Annual Rodman & Renshaw ...
Pieris Pharmaceuticals to Present at the 20th Annual Rodman & Renshaw Global Investment Conference BOSTON, Aug. 30, 2018 (GLOBE NEWSWIRE) -- Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for cancer, respiratory and other diseases, announced today that Stephen Yoder, President and Chief Executive Officer, will present at the 20th Annual Rodman & Renshaw Global Investment Conference on Wednesday, September 5th at 12:05PM EDT at the St. Regis New York Hotel in New York. A webcast of t...
Pieris Pharmaceuticals Reports Second Quarter 2018 Financial Results a...
Pieris Pharmaceuticals Reports Second Quarter 2018 Financial Results and Provides Corporate Update COMPANY TO HOST AN INVESTOR CONFERENCE CALL ONTHURSDAY, AUGUST 9, 2018 AT 8:00 AM EDT BOSTON, Aug. 09, 2018 (GLOBE NEWSWIRE) -- Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for cancer, respiratory and other diseases, today reported financial results for the second quarter of 2018 ended June 30, 2018, and provided an update on the Company's recent and future developme...
Pieris Pharmaceuticals to Present at the 2018 Wedbush PacGrow Healthca...
Pieris Pharmaceuticals to Present at the 2018 Wedbush PacGrow Healthcare Conference BOSTON, Aug. 08, 2018 (GLOBE NEWSWIRE) -- Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for cancer, respiratory and other diseases, announced today that Allan Reine, Senior Vice President and Chief Financial Officer of Pieris Pharmaceuticals, Inc., will present at the 2018 Wedbush PacGrow Healthcare Conference in New York on Wednesday, August 15, 2018 at 9:45AM EDT. A webcast of the company’s prese...
Pieris Pharmaceuticals to Host Second Quarter 2018 Investor Call and C...
Pieris Pharmaceuticals to Host Second Quarter 2018 Investor Call and Corporate Update on August 9, 2018 BOSTON, Aug. 01, 2018 (GLOBE NEWSWIRE) -- Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for cancer, respiratory and other diseases, announced today that it will host a second quarter 2018 investor call on Thursday, August 9, 2018 at 8:00 AM (EDT) to discuss financial results and provide a corporate update. To access the call, participants may dial 877-407-8920 (US & Canada) or ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.